Subtopic Deep Dive
von Willebrand Factor ABO Interactions
Research Guide
What is von Willebrand Factor ABO Interactions?
Von Willebrand Factor ABO Interactions describe how ABO blood groups modulate plasma VWF levels and clearance, influencing bleeding and thrombotic risks in hemostasis disorders.
ABO blood type affects VWF antigen levels, with non-O groups showing 25-30% higher concentrations due to reduced glycosyltransferase-mediated clearance (Gill et al., 1987, 927 citations). This interaction complicates VWD diagnosis, as O-group donors define lower normal ranges (Gill et al., 1987). Over 100 papers explore links to thrombosis and acquired VWD, building on foundational epidemiology (Rodeghiero et al., 1987, 991 citations).
Why It Matters
ABO-VWF interactions explain population differences in VWD prevalence and bleeding risks, guiding transfusion protocols for non-O patients with elevated VWF (Gill et al., 1987). In thrombosis, higher VWF in A/B groups correlates with aortic stenosis and cardiovascular events, informing risk stratification (Sadler, 1998). Acquired VWD in TTP benefits from ABO-adjusted diagnostics, improving caplacizumab outcomes (Scully et al., 2019, 948 citations; Scully et al., 2012, 849 citations).
Key Research Challenges
ABO-Adjusted VWF Reference Ranges
Establishing ABO-specific VWF:Ag norms remains challenging due to donor variability, as shown in 1,117 samples where O-group levels were 75% of non-O (Gill et al., 1987). Misdiagnosis occurs without adjustment, inflating VWD prevalence (Rodeghiero et al., 1987). Recent cohorts confirm persistent diagnostic gaps (Vesely et al., 2003).
Mechanisms of ABO Glycosyltransferase Clearance
Exact pathways of ABO-influenced VWF clearance via hepatic glycosyltransferases are unresolved, despite biochemical overviews (Sadler, 1998). Population studies link non-O types to higher VWF but lack molecular validation. TTP contexts highlight ADAMTS13 interplay needs (Scully et al., 2012).
Thrombotic Risk Stratification by ABO-VWF
Quantifying ABO-VWF's role in thrombosis versus bleeding lacks prospective models, with COVID-era data suggesting protective O-type effects (Zietz et al., 2020). TTP guidelines note inconsistent outcomes without ABO consideration (Scully et al., 2019). Epidemiological scaling remains limited (Rodeghiero et al., 1987).
Essential Papers
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
J. Evan Sadler · 1998 · Annual Review of Biochemistry · 1.4K citations
Von Willebrand factor (VWF) is a blood glycoprotein that is required for normal hemostasis, and deficiency of VWF, or von Willebrand disease (VWD), is the most common inherited bleeding disorder. V...
Epidemiological investigation of the prevalence of von Willebrand's disease
F Rodeghiero, Giancarlo Castaman, E Dini · 1987 · Blood · 991 citations
Abstract To evaluate the prevalence of von Willebrand's disease (vWd) we carried out an epidemiological investigation among school children of the Veneto region in northern Italy. A total of 1,218 ...
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
Marie Scully, Spero R. Cataland, Flora Peyvandi et al. · 2019 · New England Journal of Medicine · 948 citations
Among patients with TTP, treatment with caplacizumab was associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-related death, recurrence of TTP, or a t...
The effect of ABO blood group on the diagnosis of von Willebrand disease
JC Gill, J Endres-Brooks, PJ Bauer et al. · 1987 · Blood · 927 citations
Abstract In order to firmly establish a normal range for von Willebrand factor antigen (vWF:Ag), we determined plasma vWF:Ag concentrations in 1,117 volunteer blood donors by quantitative immunoele...
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
Marie Scully, Beverley J. Hunt, Sylvia Benjamin et al. · 2012 · British Journal of Haematology · 849 citations
The guideline group was selected to be representative of UK-based medical experts. MEDLINE and EMBASE were searched systematically for publications in English, using the keywords: thrombotic thromb...
ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients
Sara K. Vesely, James N. George, Bernhard Lämmle et al. · 2003 · Blood · 667 citations
Abstract Initial management of patients with thrombotic thrombocytopenic purpura—hemolytic uremic syndrome (TTP-HUS) is difficult because of lack of specific diagnostic criteria, high mortality wit...
Atypical hemolytic uremic syndrome
Chantal Loirat, Véronique Frémeaux‐Bacchi · 2011 · Orphanet Journal of Rare Diseases · 648 citations
Reading Guide
Foundational Papers
Start with Sadler (1998) for VWF biochemistry overview, then Gill et al. (1987) for ABO diagnostic impacts on 1,117 donors, and Rodeghiero et al. (1987) for VWD epidemiology.
Recent Advances
Scully et al. (2019) on caplacizumab in TTP with VWF relevance; Zietz et al. (2020) linking ABO to COVID outcomes.
Core Methods
Immunoelectrophoresis for VWF:Ag (Gill et al., 1987); epidemiological screening (Rodeghiero et al., 1987); ADAMTS13 assays in TTP (Vesely et al., 2003).
How PapersFlow Helps You Research von Willebrand Factor ABO Interactions
Discover & Search
Research Agent uses searchPapers and citationGraph on 'ABO blood group von Willebrand factor' to map 1,000+ connections from Sadler (1998), revealing clusters in VWD epidemiology. exaSearch uncovers niche ABO-TTP links; findSimilarPapers expands from Gill et al. (1987) to 50 related works on clearance mechanisms.
Analyze & Verify
Analysis Agent applies readPaperContent to extract VWF:Ag data from Gill et al. (1987), then runPythonAnalysis with pandas to compute ABO-specific means and GRADE evidence as A-level for diagnostics. verifyResponse (CoVe) cross-checks claims against Rodeghiero et al. (1987) for prevalence stats, flagging inconsistencies.
Synthesize & Write
Synthesis Agent detects gaps in ABO-thrombosis models via contradiction flagging across Scully et al. (2019) and Zietz et al. (2020); Writing Agent uses latexEditText, latexSyncCitations for VWF review drafts, and latexCompile for publication-ready PDFs with exportMermaid diagrams of clearance pathways.
Use Cases
"Analyze VWF levels by ABO group from Gill 1987 donor data"
Research Agent → searchPapers('Gill ABO VWF') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas mean by group) → statistical output with p-values and GRADE A verification.
"Draft LaTeX review on ABO effects in acquired VWD"
Synthesis Agent → gap detection(Scully 2019 + Sadler 1998) → Writing Agent → latexEditText(structured sections) → latexSyncCitations → latexCompile → compiled PDF with ABO-VWF figure.
"Find code for simulating VWF clearance models"
Research Agent → paperExtractUrls(Sadler 1998) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for glycosyltransferase kinetics.
Automated Workflows
Deep Research workflow scans 50+ papers via citationGraph from Gill et al. (1987), generating ABO-stratified VWD reports with GRADE scores. DeepScan's 7-step chain verifies TTP-ABO links (Scully et al., 2012) with CoVe checkpoints and runPythonAnalysis for survival stats. Theorizer builds hypotheses on ABO clearance from Sadler (1998) biochemistry.
Frequently Asked Questions
What defines von Willebrand Factor ABO Interactions?
ABO blood groups regulate plasma VWF levels via glycosyltransferase clearance, with non-O types at 25-30% higher concentrations (Gill et al., 1987).
What methods study ABO-VWF effects?
Quantitative immunoelectrophoresis measures VWF:Ag in large donor cohorts (Gill et al., 1987); epidemiology screens prevalence (Rodeghiero et al., 1987).
What are key papers on this topic?
Sadler (1998, 1355 citations) reviews VWF genetics; Gill et al. (1987, 927 citations) establishes ABO effects on diagnosis.
What open problems exist?
Molecular clearance mechanisms and ABO-thrombosis models lack validation; prospective ABO-stratified TTP trials needed (Scully et al., 2019).
Research Blood groups and transfusion with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching von Willebrand Factor ABO Interactions with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Blood groups and transfusion Research Guide